Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway

Viking Therapeutics, Inc.

2025-Q2 EPS reported -$0.99

Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.
Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.
Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.
Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.
Amylin agonist program progressing; IND filing planned for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.